Trials / Completed
CompletedNCT03001310
Gene Therapy for Achromatopsia (CNGB3)
An Open Label, Multi-centre, Phase I/II Dose Escalation Trial of a Recombinant Adeno-associated Virus Vector (AAV2/8-hCARp.hCNGB3) for Gene Therapy of Adults and Children With Achromatopsia Owing to Defects in CNGB3
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 23 (actual)
- Sponsor
- MeiraGTx UK II Ltd · Industry
- Sex
- All
- Age
- 3 Years
- Healthy volunteers
- Not accepted
Summary
A clinical trial of AAV - CNGB3 retinal gene therapy for patients with achromatopsia
Detailed description
CNGB3 retinal gene therapy for patients with achromatopsia
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | AAV - CNGB3 | Comparison of different dosages of AAV-CNGB3 |
Timeline
- Start date
- 2017-01-16
- Primary completion
- 2019-10-25
- Completion
- 2019-10-25
- First posted
- 2016-12-23
- Last updated
- 2023-03-08
- Results posted
- 2023-03-08
Locations
2 sites across 2 countries: United States, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03001310. Inclusion in this directory is not an endorsement.